Evidence map›Paper›PMID 35944154›Full record

ArticleBiomacromolecules2022

Fluorescence Lifetime Measurement of Prefibrillar Sickle Hemoglobin Oligomers as a Platform for Drug Discovery in Sickle Cell Disease.

Nagamani Vunnam, Scott Hansen, Dillon C Williams, MaryJane Olivia Been, Chih Hung Lo, Anil K Pandey, Carolyn N Paulson, John A Rohde, David D Thomas, Jonathan N Sachs and 1 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomacromolecules, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Phenotypic screening of the ReFRAME drug repurposing library to discover new drugs for treating sickle cell disease.Proceedings of the National Academy of Sciences of the United States of America · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Nagamani VunnamDepartment of Biomedical Engineering, University of Minnesota, Minneapolis, Minnesota 55455, United States.
Scott HansenDepartment of Biomedical Engineering, University of Minnesota, Minneapolis, Minnesota 55455, United States.
Dillon C WilliamsDepartment of Biomedical Engineering, University of Minnesota, Minneapolis, Minnesota 55455, United States.
MaryJane Olivia BeenDepartment of Biomedical Engineering, University of Minnesota, Minneapolis, Minnesota 55455, United States.
Chih Hung LoDepartment of Biomedical Engineering, University of Minnesota, Minneapolis, Minnesota 55455, United States.
Anil K PandeyDepartment of Biomedical Engineering, University of Minnesota, Minneapolis, Minnesota 55455, United States.
Carolyn N PaulsonDepartment of Biomedical Engineering, University of Minnesota, Minneapolis, Minnesota 55455, United States.ORCID 0000-0001-8564-7345
John A RohdeDepartment of Biochemistry, Molecular Biology, and Biophysics, University of Minnesota, Minneapolis, Minnesota 55455, United States.
David D ThomasDepartment of Biochemistry, Molecular Biology, and Biophysics, University of Minnesota, Minneapolis, Minnesota 55455, United States.
Jonathan N SachsDepartment of Biomedical Engineering, University of Minnesota, Minneapolis, Minnesota 55455, United States.ORCID 0000-0003-1403-5960
David K WoodDepartment of Biomedical Engineering, University of Minnesota, Minneapolis, Minnesota 55455, United States.ORCID 0000-0001-5225-2144
University of Minnesota · US

Funding

Developing a multiscale understanding of biophysical processes in sickle cell diseaseR01HL132906 · NHLBI · UNIVERSITY OF MINNESOTA · PI WOOD, DAVID KEVIN · 2017 to 2024
$4.6M
Understanding the structural dynamics of TNF receptorsR35GM131814 · NIGMS · UNIVERSITY OF MINNESOTA · PI SACHS, JONATHAN N · 2019 to 2023
$2.0M
HbS oligomers as a therapeutic target in sickle cell diseaseR21HL152313 · NHLBI · UNIVERSITY OF MINNESOTA · PI WOOD, DAVID KEVIN · 2020 to 2021
$412k
NHLBI NIH HHS R01 HL132906NHLBI NIH HHS R21 HL152313NIGMS NIH HHS R35 GM131814
6 · The paper itself

Abstract

The molecular origin of sickle cell disease (SCD) has been known since 1949, but treatments remain limited. We present the first high-throughput screening (HTS) platform for discovering small molecules that directly inhibit sickle hemoglobin (HbS) oligomerization and improve blood flow, potentially overcoming a long-standing bottleneck in SCD drug discovery. We show that at concentrations far below the threshold for nucleation and rapid polymerization, deoxygenated HbS forms small assemblies of multiple α

Indexed as

Anemia, Sickle CellHemoglobin, SickleDrug DiscoveryHemoglobinsHumansOxygenHemoglobinsHemoglobin, SickleOxygen

Identifiers

PMID35944154
PMCPMC9472799
OpenAlexW4292333017

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.